EP4199920A4 - ORODISPERSIBLE FILM FORMULATIONS COMPRISING HIGH DOSES OF ELETRIPTAN - Google Patents

ORODISPERSIBLE FILM FORMULATIONS COMPRISING HIGH DOSES OF ELETRIPTAN Download PDF

Info

Publication number
EP4199920A4
EP4199920A4 EP21858726.9A EP21858726A EP4199920A4 EP 4199920 A4 EP4199920 A4 EP 4199920A4 EP 21858726 A EP21858726 A EP 21858726A EP 4199920 A4 EP4199920 A4 EP 4199920A4
Authority
EP
European Patent Office
Prior art keywords
eletriptan
high doses
film formulations
orodispersible film
orodispersible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21858726.9A
Other languages
German (de)
French (fr)
Other versions
EP4199920A1 (en
Inventor
Serdar Unlu
Mustafa KOKTURK
Filiz Demir
Yasemin SAHIN
Mehmet Malkoc
Cansu MAGAZACI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ali Raif Ilac Sanayi AS
Original Assignee
Ali Raif Ilac Sanayi AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ali Raif Ilac Sanayi AS filed Critical Ali Raif Ilac Sanayi AS
Publication of EP4199920A1 publication Critical patent/EP4199920A1/en
Publication of EP4199920A4 publication Critical patent/EP4199920A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21858726.9A 2020-08-19 2021-06-18 ORODISPERSIBLE FILM FORMULATIONS COMPRISING HIGH DOSES OF ELETRIPTAN Pending EP4199920A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/13084A TR202013084A1 (en) 2020-08-19 2020-08-19 MOUTH MELTING FILM FORMULATIONS WITH HIGH DOSES OF ELETRIPTAN
PCT/TR2021/050624 WO2022039692A1 (en) 2020-08-19 2021-06-18 Orodispersible film formulations comprising high doses of eletriptan

Publications (2)

Publication Number Publication Date
EP4199920A1 EP4199920A1 (en) 2023-06-28
EP4199920A4 true EP4199920A4 (en) 2024-10-02

Family

ID=80350558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21858726.9A Pending EP4199920A4 (en) 2020-08-19 2021-06-18 ORODISPERSIBLE FILM FORMULATIONS COMPRISING HIGH DOSES OF ELETRIPTAN

Country Status (3)

Country Link
EP (1) EP4199920A4 (en)
TR (1) TR202013084A1 (en)
WO (1) WO2022039692A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374448A1 (en) * 2010-04-06 2011-10-12 Labtec GmbH Oral film formulation
US20120148689A1 (en) * 2007-06-19 2012-06-14 Todd Maibach Film comprising active drugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120148689A1 (en) * 2007-06-19 2012-06-14 Todd Maibach Film comprising active drugs
EP2374448A1 (en) * 2010-04-06 2011-10-12 Labtec GmbH Oral film formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PALLAVI K. ET AL: "FORMULATION AND EVALUATION OF FAST DISSOLVING FILMS OF ELETRIPTAN HYDROBROMIDE", INTERNATIONAL JOURNAL OF CURRENT PHARMACEUTICAL RESEARCH, vol. 9, no. 2, 1 March 2017 (2017-03-01), pages 59, XP055908654, Retrieved from the Internet <URL:http://innovareacademics.in/journals/index.php/ijcpr/article/viewFile/17386/9680> DOI: 10.22159/ijcpr.2017v9i2.17386 *
See also references of WO2022039692A1 *

Also Published As

Publication number Publication date
EP4199920A1 (en) 2023-06-28
TR202013084A1 (en) 2022-03-21
WO2022039692A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
CY1118059T1 (en) ANTIBODY COMPOSITIONS BASED ON FAT FOR TREATMENT OF PULMONARY INFECTIONS
EP3934633A4 (en) COMPOSITIONS AND METHODS OF USE INCLUDING SUBSTANCES HAVING NEURAL PLASTICITY ACTIONS ADMINISTERED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS
JOP20200154A1 (en) Pyrido-pyriminone compounds and derivatives have new benzyl amino substitutions as SOS1 inhibitors
CY1116123T1 (en) HIGH-DOSE IBANDRONAT PREPARATION
CY1111726T1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ASTHMA
DE60334773D1 (en) FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
CY1107894T1 (en) GABA analogue prodrugs, their compositions and uses
ATE418324T1 (en) MUCOADHESIVE FORMULATION CONTAINING XYLOGLUCAN FOR MEDICAL DEVICES AND PHARMACEUTICAL DOSAGE FORMS
MA55033A (en) THERAPEUTIC ANTIBODY FORMULATION
CY1110906T1 (en) PHARMACEUTICAL COMPOSITION FOR NON-ADMINISTRATION OF FENTANYL
DE50005529D1 (en) ORAL PHARMACEUTICAL FORMS FOR ADMINISTRATING A FIXED COMBINATION OF TRAMADOL AND DICLOFENAC
AR018862A1 (en) PHARMACEUTICAL FORMULATION OF PROLONGED RELEASE, IMPROVED FOR THE ORAL ADMINISTRATION OF NEFAZODONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; ORAL DOSAGE FORM THAT UNDERSTANDS AND USE OF SUCH FORMULATION TO PREPARE THE SUCH DOSAGE FORM
EP3773900A4 (en) HINOKITIOL ANALOGS, METHODS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP3867271A4 (en) ANTI-RSV ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
EA202192199A1 (en) COMPOSITIONS CONTAINING CINNAMIC ACID AND METHODS OF THEIR APPLICATION
CY1116274T1 (en) TRIAZOLI PRODUCT FOR USE IN TREATMENT OF NEUROPATHIC PAIN AND Fibromyalgia
JOP20250048A1 (en) Formulations for oral administration
EP4199920A4 (en) ORODISPERSIBLE FILM FORMULATIONS COMPRISING HIGH DOSES OF ELETRIPTAN
EP4355259A4 (en) SUBGINGIVAL DRUG DELIVERY TRAY
EP3946277A4 (en) ORODISPERSIBLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN
SE0200657D0 (en) Novel Formulation
EP4297590A4 (en) ORAL DOSE COMPOSITIONS OF TRIBUTYRIN FOR THERAPEUTIC GENERATION OF BUTYRATE IN THE INTESTINE
EP4259713A4 (en) FORMULATIONS FOR THE ADMINISTRATION OF BIOACTIVE AGENTS
JOP20240074A1 (en) Enzalutamide oral liquid formulations
MA71620A (en) ANTI-TL1A ANTIBODY FORMULATIONS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240904

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/06 20060101ALI20240829BHEP

Ipc: A61K 9/70 20060101ALI20240829BHEP

Ipc: A61K 31/404 20060101AFI20240829BHEP